TY - JOUR T1 - Comparative efficacy of different groups of drugs for the treatment of bronchial asthma in combination with allergic rhinitis JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P3469 AU - Natalia Zhukova AU - Marina Zakharova AU - Olga Krjuchkova Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P3469.abstract N2 - The study included 90 patients (64 (71.1 %) women and 26 (28.9%) men) suffering from asthma and AR. In 67 (74.4%) patients AR preceded the appearance of asthma, in all cases for AR was moderate. Patients with other concomitant diseases were excluded.The symptoms of BA were at night asthma 77 (85.5 %), cough with expectoration of mucous viscous sputum 60 (66.6 %) , shortness of breath on exertion 73 (81.1 %) of the manifestations observed rhinorrhea AR 68 (75 5%), nasal congestion, 22 (24.5%), itchy nose 53 (58.8 %), sneezing fits 71 (78.8 %).For the treatment of Asthma were used ( fluticasone / salmeterol ), for the treatment of AR all patients were used fluticasone furoate . In addition 30 (33.3 %) patients (group 1) were received montelukast 10 mg per day, 30 (33.3 %) patients (group 2 ) were received fexofenadine 120 mg a day every day , the remaining 30 patients accounted for the control group .The study was conducted for 3 months.During this time, all patients had a positive trend in the form of a reduction in symptoms from both BA and from the AR.However, patients in group 1 less frequent nocturnal asthma (40%) than in 2 (60%) and 3 (60%) groups, cough (26.6%) and dyspnea (46.6%) had less than 2 in (43.3 % of 50%) and 3 (43.3% of 66.6%), respectively. Also less frequent nasal congestion, nasal itching and sneezing.Furthermore, when receiving montelukast patients did not experience drowsiness, unlike 6 (20 %) patients treated with fexofenadine.Thus, the purpose of the appointment of fexofenadine montelukast is preferably in combination with fluticasone furoate in treatment of the patients suffering from asthma comorbidity and AR . ER -